Literature DB >> 1940440

Gene rearrangement studies in the diagnosis of primary systemic and nodular primary localized cutaneous amyloidosis.

K Grünewald1, N Sepp, K Weyrer, K Lhotta, H Feichtinger, G Konwalinka, S M Breathnach, H Hintner.   

Abstract

Difficulties may arise in the diagnosis of patients with clinical features suggestive of plasma cell dyscrasia-related amyloidosis (amyloidosis L), but without evidence of a paraprotein. We have employed gene rearrangement methodology to demonstrate the clonality of bone marrow cells not only in a patient with myeloma-associated systemic amyloidosis, but also in a patient with "primary" systemic amyloidosis without overt myeloma or a detectable paraprotein. Furthermore, we have shown the clonality of the amyloid-producing plasma cells within a skin nodule of a patient with primary localized cutaneous amyloidosis; by contrast, clonal rearrangement was not detected in bone marrow cells from this patient. This finding provides definitive proof that organ-limited nodular primary localized cutaneous amyloid deposits arise in relation to cutaneous plasmacytomas. Gene rearrangement studies may enable early diagnosis and initiation of treatment in patients with systemic amyloidosis L, as well as their differentiation from patients with organ-limited nodular cutaneous amyloidosis, who do not require aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940440     DOI: 10.1111/1523-1747.ep12484004

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

1.  Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction.

Authors:  T Miyamoto; T Kobayashi; M Makiyama; S Kitada; M Fujishima; Y Hagari; M Mihara
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

Review 2.  Localized AL amyloidosis: a suicidal neoplasm?

Authors:  Per Westermark
Journal:  Ups J Med Sci       Date:  2012-02-15       Impact factor: 2.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.